Heart disease continues to be the leading cause of death in the United States. The demand for cardiovascular bypass procedures increases annually. Expanded polytetrafluoroethylene is a popular material for replacement implants, but it does have drawbacks such as high thrombogenicity and low patency, particularly in small diameter grafts. Hyaluronan, a naturally occurring polysaccharide in the human body, is known for its wound healing and anticoagulant properties. In this work, we demonstrate that treating the luminal surface of expanded polytetrafluoroethylene grafts with hyaluronan improves hemocompatibility without notably changing its mechanical properties and without significant cytotoxic effects. Surface characterization such as ATR-FTIR and contact angle goniometry demonstrates that hyaluronan treatment successfully changes the surface chemistry and increases hydrophilicity. Tensile properties such as elastic modulus, tensile strength, yield stress and ultimate strain are unchanged by hyaluronan enhancement. Durability data from flow loop studies demonstrate that hyaluronan is durable on the expanded polytetrafluoroethylene inner lumen. Hemocompatibility tests reveal that hyaluronan-treated expanded polytetrafluoroethylene reduces blood clotting and platelet activation. Together our results indicate that hyaluronan-enhanced expanded polytetrafluoroethylene is a promising candidate material for cardiovascular grafts.
Introduction
Cardiovascular complications such as atherosclerosis, myocardial infarction, and peripheral vascular disease continue to be major causes of death in the United States, responsible for 31.9% of total mortality in 2010. 1 The number of patients who have undergone surgeries such as coronary revascularization is expected to increase with a growing aged population. 1, 2 Although autogenous sources and allografts are often preferred, scarcity and increasing demand necessitate a more sustainable solution. 1, 3 Synthetic materials such as expanded polytetrafluoroethylene (ePTFE) are popular for vascular bypasses of occluded blood vessels. 4, 5 ePTFE has also been in use for decades for various biomedical applications such as hernia membranes, hemodialysis, and surgical sutures. 5, 6 The strong fluorine backbone on the carbon chain allows the polymer to withstand biodegradation. 5 Despite its biostability, the hydrophobic surface of ePTFE is known to promote protein adsorption and platelet activation, which cause graft failure due to thrombosis. 7 Large diameter (>8 mm) synthetic vascular grafts overcome thrombosis with a high blood flow rate, but surgical revision is still common with a five-year primary patency rate as low as 56%. 4, 8 For small diameter (<6 mm) synthetic vascular grafts, occlusion is more prevalent. 4, 5, 9 The five-year patency rate for small vascular grafts can be lower than 30%. 8 Furthermore, ePTFE is a poor surface for endothelial cell adhesion, which deprives the biomaterials of a naturally anti-thrombogenic endothelial lining. 7 Extensive work has focused on enhancing ePTFE to improve its hemocompatibility. 5 Surface modification is commonly attempted to prevent blood clotting and promote endothelialization. 10, 11 A widely adopted technique is enhancing the blood contacting interface with the anticoagulant glycosaminoglycan (GAG) heparin. 10 Heparin can also promote adhesion and proliferation of endothelial cells, which is crucial in vessel remodeling. 10 Hyaluronan (HA) is another GAG with anticoagulant properties, but which has not been studied as extensively as heparin for vascular applications. HA is a nonbranching, anionic, and nonsulfated polysaccharide that is ubiquitous in the human body. High concentrations of HA are found in both synovial and cerebrospinal fluids, which gives them their lubricious properties. 12 The effects of HA on endothelial cells and platelet adhesion have been found to be highly dependent on its molecular weight. 13 HA is also present in blood vessels along the inner luminal layer and is known to be active during inflammatory and wound healing processes. 14 Research has shown HA can promote the growth of smooth muscle and endothelial cells after vascular injury. 15 HA coatings on titanium implants have been shown to reduce thrombosis. 16 HA-based hydrogels have been used to support neovascularization during in vivo studies. 17 Prawel et al. 18 demonstrated that diisocyanate crosslinked HA can prevent blood clotting and platelet activation when the modified polysaccharide forms an interpenetrating network with linear low-density polyethylene.
Based on previous work, this study investigates the potential of HA for improving the hemocompatibility of ePTFE vascular grafts. 18 High molecular weight HA (HMW-HA), which is commonly found in healthy tissues and known to inhibit inflammation, was used to enhance the inner lumen of commercial ePTFE cardiovascular grafts. 14, 20 The GAG was crosslinked with an industrial diisocyanate to create a persistent polymeric network of HA-enhanced ePTFE (HA-ePTFE). Surface and material characterizations were performed to verify HA presence on the ePTFE graft. Mechanical testing determined how HA enhancement affects some of the material properties. In vitro hemocompatibility studies evaluated anti-thrombogenic behavior of HA-ePTFE.
Materials and methods

Hyaluronan enhancement of ePTFE
The approach to introducing HA into the ePTFE is adapted from prior work. 18 Briefly, sodium hyaluronate at 750 kDa (Lifecore Biomedical) and cetyltrimethylammonium bromide (CTAB) (Fisher Scientific) were each dissolved in distilled (DI) water. The CTAB solution was slowly added to the HA solution while stirring to form a hyaluronancetyltrimethylammonium (HA-CTA) precipitate. The HA-CTA precipitate was washed with DI water to remove CTAB residue. The purified HA-CTA was granulated, dried, and dissolved in ethanol creating a 0.4% (w/v) solution.
Commercial ePTFE peripheral cardiovascular grafts (Bard IMPRA! 70S10, 10 mm diameter) were treated with the HA-CTA/ethanol solution using an airbrush (Powermate); 5 ml of the HA-CTA solution was sprayed into the inner lumen of a 2-cm long ePTFE graft between 20 and 25 psi. Spraying was done from both ends of the tubing to ensure uniformity. The HA-CTA-treated graft was dried under vacuum at 50 C to fully remove ethanol. HA-CTA was then crosslinked by submerging the graft in a 2% (v/v) poly(hexamethylene diisocyanate) (Desmodur V R 3200) (HDI)/acetone solution for 1 h at 50 C under nitrogen purge. The samples were then removed from the crosslinking solution and further cured for 1 h under vacuum at 50 C. Following this, excess un-crosslinked HDI was washed away by stirring the sample in acetone for 5 min. The CTA complex was removed by sonicating the treated ePTFE sample in 0.2 M NaCl DI water/ethanol (1:1) solutions for 4 h, allowing the sonicator to heat up to 45 C. Uncrosslinked HA compounds were further removed by incubating the treated ePTFE in DI water/ethanol (3:2) solution for at least 8 h, before a final wash by sonicating in DI water for 30 min.
Surface characterization
Surface hydrophilicity was assessed by measuring contact angles via the captive bubble technique using a goniometer (260-F4 Rame´-Hart Instrument). Untreated and HA treated samples (n ¼ 3) were soaked for at least 1 h in DI water to swell the HA at the surface before testing in an aqueous environment. We were interested in surface characteristics, not tubular graft performance, so test samples were then cut from the tubular grafts, flattened, and carbon taped on a glass slide with the inner lumen facing outward. The glass slide, along with the sample, was submerged and suspended in DI water. An air bubble was introduced to the sample's surface and the static contact angle was measured immediately. Receding angle was measured by expanding the air bubble until a stable measurement was reached, and advancing angle was measured by minimizing the air bubble until a constant value was obtained. Reported angles were measured between the solid-liquid interface, which is the contact point of glass and liquid.
Attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) (Nicolet iS50) was used to qualitatively analyze the functional groups on the surface of plain and HA-treated ePTFE. Untreated and HA-ePTFE grafts were cut and flayed open. The inner lumen of the graft was placed face down on the ATR diamond for the spectrometer and 32 scans were performed.
Circumferential tensile testing
Monotonic tensile testing was performed in accordance to the ISO/ANSI, 7198 for determining whether HA treatment affected the tensile properties of the ePTFE graft. Samples were hydrated in DI water for 1 h. The tubular graft was then cut into 10 mm longitudinal lengths (cylindrical rings) (N ¼ 3), threaded on pins, and then mounted on an Instron, 4442 with a 5 kN load cell (Figure 1 ). The preload of 1 N was applied for 1 min. The tubular specimen was then elongated at 100 mm/min until it ruptured. Load and displacement were recorded to calculate the elastic modulus, engineering tensile stress, yield stress, and engineering strain at failure. The duration of the experiment starting from mounting the samples onto pins to when the samples ruptured was no more than 10 min to ensure the HA would not dehydrate significantly. The engineering stress (r) and strain (e) were calculated as follows
F is force, t is the graft thickness, L is the longitudinal length of the sample, Dl is the change in radial length, and l 0 is the initial radial length. The dimensions are labeled in the schematic of Figure 1 . The Young's modulus was calculated from the slope of the linear elastic region, which was the initial 10% of strain. Yield stress was determined by 0.2% strain offset along the elastic region.
Mechanical stability of HA on ePTFE
To perform a preliminary assessment of the mechanical stability of HA on ePTFE, a hyper-physiological constant shear (55 dynes/cm 2 ) was applied to the HA-ePTFE. Untreated ePTFE was the negative control. HA-ePTFE samples (n ¼ 3) were cut, flattened, placed . Such a high shear stress was picked to simulate accelerated wear on the sample. The water reservoir contained 1% penicillin/streptomycin (Gibco V R ) and was replaced daily to prevent contamination. Wall shear stress (s) was determined using the equation below, which is based on the principles governing fluid flow under Poiseuille's law
Q is flow rate and r is the radius of the silicone tubing. Viscosity (g) of water was assumed to be 0.6913 mPaÁs at 37 C. 21 After seven days, the amount of HA remaining on samples was determined by thermogravimetric analysis (TGA), comparing to unstressed samples. TGA was performed on test samples and controls in a thermogravimetric analyzer (TA 2950) at a heating rate of 10 C/min under air purge. Material loss between 200 and 450 C was calculated to determine the composition of HA-ePTFE samples.
Static whole blood clotting
Thrombogenicity was evaluated by studying blood interaction with HA-ePTFE. 22 Briefly, 8 mm diameter ePTFE test samples were made using a biopsy punch (Acuderm) and then hydrated in DI water for 1 h prior to the experiment. Human blood was collected from healthy donors by a certified phlebotomist (Colorado State University Health Network). The donors had not taken any medication, including aspirin, for at least two weeks. Blood was collected by venipuncture directly into an un-treated 3-mL collection tube (BC Vacutainer V R ) and used immediately. Untreated and HA-treated ePTFE samples (n ¼ 3) were placed in tissue culture polystyrene (TCPS) 24-well plates (Greiner CELLSTAR V R ). Blood droplets (10 mL) were pipetted onto the surface of each sample and the TCPS wells. TCPS was used as a control because its surface is known to promote blood clotting. 23 Blood was left to clot for 30 and 60 min on the samples and control; 1000 mL of DI water was added to each well and the solutions were gently agitated on a shaker plate (Titer) for 30 s to free non-clotted blood. The samples rested for 5 min allowing further free hemoglobin that was not trapped in the blood clot to be released into DI water; 2 mL of whole blood was also mixed with 200 mL of DI water and used as a reference representing absorbance of unclotted blood; 202 lL of the blood solution from the ePTFE samples and the TCPS wells were transferred into a 96-well plate for absorbance at 540 nm using a plate reader (FLUOstar Omega). Absorbance was inversely correlated to blood clotting (darker samples ¼ more clotting). A sample with more clots would have a lighter red color in its solution, because more hemoglobin is trapped in the clot.
Platelet activation
Platelets are the first cells to be involved in the clotting cascade. Studying their behavior on biomaterials is important in hemocompatibility assessment. Briefly, 8 mm diameter test samples were punched from treated sample material using a biopsy punch (Acuderm). TCPS was again chosen as our positive control. TCPS "pucks" (also 8 mm diameter) were punched from Greiner CELLSTAR V R materials. Untreated and HA-treated ePTFE grafts, and TCPS pucks (n ¼ 3), were sterilized with 70% ethanol, dried, then placed in TCPS 24-well plates (Greiner CELLSTAR V R ); 1 mL of DI water was added to each well to allow the HA to hydrate for 1 h, then removed just prior to the actual experiment. Whole blood was collected, as described above in the whole blood study, into ethylenediaminetetraacetic acid (EDTA) coated vials (BD Vacutainer V R ) to prevent coagulation. Blood was centrifuged at 150g for 15 min to separate plasma from blood; 1 mL of plasma was pipetted into each sample-containing well and the well plate was stirred on a shaker at 100 r/min for 2 h inside a cellculturing incubator (37 C, 5% CO 2 ). Afterward, plasma was gently aspirated and samples were rinsed twice with phosphate-buffered saline.
Platelets adhering to the samples were fixed according to a previously published method. 22 Briefly, samples were submerged in a 3% (v/v) glutaraldehyde, 0.1 M sucrose, and 0.1 M sodium cacodylate aqueous solution for 45 min; they were then placed in a secondary fixative solution containing only sodium cacodylate and sucrose for at least 1 h. Platelets were dehydrated by incubating the samples in consecutive ethanol/DI water solutions (35, 50, 70, 95 , and 100% ethanol) for 10 min each. The samples were then dried in a desiccator under vacuum for at least 24 h. They were coated with 10 nm of gold and imaged at 5 kV under a scanning electron microscope (SEM) (JEOL JSM 6500F). SEM images were taken in five different areas per fixed sample at three different magnifications (700Â, 2500Â, 7000Â). Platelets were counted based on their morphology using ImageJ (NIH). Platelet activation chronology was quantified by dividing their morphology into the following six stages using a previously published method: [24] [25] [26] (1) round: discoid shape representing platelets that were not activated. (2) (4) spreading: one or more pseudopodia flattened, and hyaloplasm spread between pseudopodia. (5) fully spreading: firm cellular adhesion with hyaloplasm extensively spread, and there are no distinct pseudopodia but granulation is observed. (6) aggregation: platelet activation and mediating factor secretion recruit more platelets, which promotes thrombus formation.
Cytotoxicity study
To ensure the HA-ePTFE is not toxic to cells, which would potentially influence the platelet activation study, lactate dehydrogenase (LDH) activity was measured in blood plasma that was incubated with ePTFE samples using a commercial assay kit (QuantiChromTM, Cat # C2LD-100). LDH is a cytosolic enzyme that is released upon cell death and its concentration in the extracellular space corresponds to the level of toxicity.
After blood plasma was incubated with samples for 2 h at 37 C and 5% CO 2 (n ¼ 5), 50 mL of plasma in each well was pipetted into a 96-well plate; 50 mL of LDH reaction solution (provided in the assay kit) was mixed with plasma in the well plate. The mixture was incubated at room temperature for 30 min before the stopping buffer (from the kit) was added to stop the reaction. Afterward, the absorbance at 490 nm was immediately measured with a spectrophotometer (FLUOstar Omega). Absorbance correlates to LDH activity. TCPS pucks were also used as a positive control. The entire experiment was conducted in a light protected environment.
Statistical analysis
Statistical analysis was performed using ANOVA with post hoc Tukey's test. A two-way ANOVA was used to analyze platelet activation with activation category as factor one and the different materials as factor two. All biological studies were repeated twice to ensure reproducibility.
Results
Surface characterization
The HA-ePTFE grafts showed a significant decrease in all contact angles compared to the plain ePTFE control group (Figure 2) . The respective static, receding, and advancing angles of untreated group are 96 AE 11 , 57 AE 1 , and 139 AE 5 . The angles for HA treated counterparts are 12 AE 8 , 22AE 3 , and 43 AE 13 , respectively. The hysteresis, which is the difference between advancing and receding angles, also appears to be significantly different between plain and HA-treated ePTFE (81  and  30 ). Based on these data, the HA treatment significantly increased the surface hydrophilicity of ePTFE, changing its inner lumen from hydrophobic to hydrophilic.
FTIR spectra (Figure 3 ) confirm the presence of HA on the treated samples. The two significant peaks appearing on the plain ePTFE at 1220 and 1150 cm bands at 1650 and 1560 cm À1 (C ¼ O, and -NH-of the carboxylate groups), 2900 and 2800 cm À1 (-CH 3 -and -CH 2 -stretching), and 3400 cm À1 (OH of the glycoside rings). Presence of HA on the luminal surface is further confirmed by bands at 1400 cm À1 (-COO-carboxylate symmetric stretch), 1320 and 1450 cm À1 (C-CH and O-CH stretching), and 1060 cm À1 (C-O-C bending).
Mechanical stability study
TGA results in Figure 4 show the results of our mechanical stability experiment. Approximately 1.56 AE 0.05% of material burns off on HA-ePTFE, while 1.66 AE 0.38% burns off HA-ePTFE under shear. The two groups are not statistically different from each other (n ¼ 3, P ¼ 0.05). Therefore, it does not appear that there is any loss of HA on the ePTFE after applying a hyper-physiological shear stress of 55 dynes/cm 2 . The fact that 0.04 AE 0.04% of untreated ePTFE burned off between the analyzed temperature range further confirms that the material loss on treated samples is HA.
Circumferential tensile data 
Whole blood clotting
The images in Figure 7 show how HA treatment affects blood clotting over time. In the first 30 min, there appears to be a noticeable amount of blood clotted at the center of the untreated ePTFE (left image, second row), while there was very little clot on the TCPS and HA-treated samples (left image, first and third row, respectively). The color of the solutions in these two groups looks slightly darker than the untreated ePTFE, suggesting more coagulation on the untreated ePTFE samples. After 60 min, large clots formed in the TCPS and untreated ePTFE wells (right image, first and second row, respectively). Maximal clotting appears to occur on TCPS; all the blood concentrated in the coagulated region leaves the color of the solution virtually clear. Similar behavior is observed on untreated ePTFE samples, but to a lesser extent. The HA-ePTFE only shows a minor blood clot at the center of its samples (right image, third row). The color of its solution remains approximately the same after 30 min, which implies that most of the blood eluted into the solution without clotting. Figure 8 presents the colorimetric data obtained from the plate reader. The amount of free hemoglobin after 30 min was significantly different between TCPS and that of whole blood, but there were no differences among TCPS, HA-ePTFE, and untreated ePTFE. After 60 min, there was a significant decrease in free hemoglobin on all the samples except for the HA-ePTFE; only minor blood clots are seen at the center of these samples, which indicates that HA treatment significantly reduces blood clotting on the surface of HA-ePTFE graft after 60 min. 
Platelet activation
Platelets on substrates were imaged using SEM to qualitatively assess cell morphology and spreading, which can provide insights into cellular adhesion (at 750Â) and activation (at 2500Â and 7000Â) (see Figure 9 ). The TCPS is nearly completely covered with platelets, often clumping together; some cells appear to have their hyaloplasm spreading pseudopodia. Higher magnification reveals many of the platelets either granulated after spreading or clumped together. A similar trend appears on plain ePTFE samples, but there was much less cellular adhesion on the plain samples. Despite this, almost all cells on these surfaces are layered on each other, forming large concentrated clumps. HA-treated ePTFE shows fewer cells on their surfaces compared to TCPS, and most platelets appear rounded and much less activated. Quantitative results in Figure 10 further reveal three distinct patterns in platelet-material interaction on each surface. HA-ePTFE demonstrates significantly fewer platelets reaching a later activation stage (>3) than other groups. Nearly half of the cells on HA-treated ePTFE are either rounded (17.5 AE 7.4%) or in their early dendritic form (34.3 AE 1.4%). Other morphologies also appeared, but in lesser amounts: spreading dendritic (18.2 AE 0.8%), spreading (3.3 AE 2.4%), fully spreading (5.7 AE 4.0%), and aggregation (20.9 AE 12.1%). No single stage was dominant and the overall distribution was dispersed. The number of platelets on TCPS gradually increased in each stage from round (3.3 AE 2.7%), dendritic (11.8 AE 7.1%), spreading dendritic (6.0 AE 3.0%), spreading (9.2 AE 2.9%), fully spreading (19.1 AE 11.0%), to aggregation (50.7 AE 3.8%). In contrast to HA-ePTFE, the vast majority of platelets have reached the final stage of aggregation on untreated ePTFE (84.4 AE 1.1%).
Cytotoxicity
There was no significant difference in LDH concentration between untreated ePTFE, HA-ePTFE and TCPS ( Figure 11 ). The presence of LDH in this assay correlates with dead cells and there was no increase in LDH activity between the TCPS negative control and the 
TCPS
Untreated ePTFE HA Treated ePTFE Figure 9 . SEM images of TCPS (1st column), Untreated ePTFE (2nd column), and HA treated ePTFE (3rd column) from the platelet activation study show significantly less platelet activation on HA-treated ePTFE. The platelets on the HA treated ePTFE are most round and least activated. Cells can be seen aggregating and spreading on ePTFE and TCPS.
other groups. Therefore, ePTFE and HA-ePTFE did not exhibit a significant toxicological effect on platelets.
Discussion
Contact angle goniometry results show that HA enhancement significantly increased ePTFE hydrophilicity. This is expected because HA is known for its high water retention. 27 Hydrophilic surfaces are often used as biomaterials because water films can support cellular adhesion while preventing adsorption of proteins that can cause thrombosis and inflammation. 28 Surface area and porosity could be altered by the HA layer. Based on the SEM images (Figure 9 ), the HA looks flat and created a smooth surface on ePTFE, but the HA-ePTFE was imaged when dry. A hydrated and swollen HA layer may appear very different. Further investigation is required to determine the topography of HA-ePTFE. Sophisticated surface characterization techniques such as atomic force microscopy could accurately map the swollen surface. They may also provide other topological features including surface roughness and stiffness.
Mechanical stability testing demonstrates that the HA layer can withstand hyper-physiological shear, as seen in the TGA results. 29 Although the flow study only lasted for seven days, the applied shear stress was over three times higher than the average physiological wall shear stress in blood vessels, which is approximately 15 dynes/cm 2 . 29 The HA layer on the ePTFE appeared to be mechanically stable despite having no chemical links between the isocyanate crosslinked HA and ePTFE. It is possible that the high porosity of ePTFE, due to its internodal space, may allow HA to penetrate and persist in the polymeric graft. Nevertheless, future work is required to better characterize the mechanism and durability of the biomaterial. Figure 11 . LDH presence shows that ePTFE and HA-enhanced ePTFE did not exhibit a significant toxicological effect on platelets (n ¼ 5, a ¼ 0.05). The amount of LDH released by all groups was statistically the same.
Surface chemical functionality is an important parameter in evaluating the interaction of blood with biomaterials. FTIR data (Figure 3) show no fluorocarbon peaks. The visible peaks and their corresponding chemical groups are associated with HA presence, as shown from previous work. 18 The TGA results indicate that the crosslinker greatly changed the thermal properties of the HA network. Literature reports the burn off temperature of HA to be no higher than 350 C, 18, 19 but the HDI-crosslinked HA required heating up to 450 C to burn the crosslinked polysaccharide. This suggests that the added bond strength seen in the polymeric network can be attributed to HDI crosslinking of HA.
Diisocyanate crosslinked biopolymers of hyaluronan have demonstrated the ability to improve biocompatibility, 18 but further research is required to understand its mechanism. The presented HA enhancement approach is one of the few where diisocyanate is used to crosslink HA, with the carboxyl group of the glucuronic acid left uncrosslinked and exposed. 30 The HA network can further expand because of mutual repulsion between the carboxyl groups within its structure, and a large free volume can be created for water penetration supporting cellular migration. 31 For example, the neural crest cell migration path is rich with HA during fetal development. 32 This can be important because migration and growth of endothelial cells are signs of vessel remodeling. Moreover, it is thought that the carboxyl terminus may be required for HA interaction with proteoglycans, essential components of the endothelial glycocalyx that protects the vascular wall from atherogenesis and atherosclerosis. 33 Our whole blood study demonstrated a marked decrease in clotting, supporting the argument for HAePTFE anti-thrombogenic properties. Although the whole blood study was a simple experiment, previous work involving protein adsorption and endothelial studies has shown the method to be a good indicator of thrombogenic potential. 34 Despite showing that HAePTFE surfaces lead to minor clotting after 60 min, the environment of the experiment is not physiologically representative and should only be used for relative comparison with the control (TCPS) and the untreated ePTFE. Blood sitting idly in dry air at ambient temperature will clot over time. Future studies will consider more physiologically relevant methods to simulate blood interactions with the HA-ePTFE graft in vivo. Such designs could also be used to model pathological effects from synthetic vascular grafts such as compliance mismatch.
Platelet activation results indicate that HA-ePTFE significantly reduces platelet activation, an important process in thrombus and fibrin formation. The LDH assay shows that platelets did not apoptose.
Furthermore, there was no significant difference in the LDH activity of control (TCPS) and treatment groups. The results indicate that the HA treatment is not toxic to platelets and that cell viability was not a factor in our platelet activation studies. Most of the platelets found on the HA-ePTFE were in the early stages of dendritic extension and spreading after 2-h incubation. The decrease in platelet adhesion may be due to the surface charge of HA. The negatively charged carboxyl group of the crosslinked HA could repulse negatively charged proteins responsible for platelet adhesion, such as adenosine diphosphate and fibrinogen, from binding.
It is possible that the rigid polystyrene used in the study partially influenced platelet activation. Platelets suspended in the plasma during incubation could have adhered to the polystyrene, become activated, and released substances that might have promoted adhesion of additional platelets from the surrounding plasma. 24 This could affect the results by overestimating the total platelet activation caused by the biomaterials. It is possible that the seemingly activated platelets on the HA-treated samples are because of this external factor. But if the reported level of platelet activation is solely due to the HA-treated surface, then that might be beneficial for cardiovascular applications. Platelets have been shown to induce transformation of endothelial progenitor cells, which participate in vascular repair and homeostasis, into endothelial cells. 35 Further analysis of platelet activation such as of P-selectin, aIIbb3, and a-granule expression is important. More quantitative analysis of platelet adhesion will be performed, perhaps by using well establish cell metabolic assays such as PicoGreen, MTT, or LDH.
Future work will look at various proteins influencing platelet activation. For example, studying thrombin activity is important because this protein is locally recruited upon platelet adhesion to promote aggregation and thrombus growth. 36 Understanding key adhesive proteins such as Von Willebrand Factor (VWF) and fibrinogen would also reveal how platelets are activated on the HA-ePTFE surface. 37 Besides conducting more physiologically representative assays to analyze thrombosis, other tests to pursue include hemolysis, inflammation, and complement activation in accordance to ISO 10993 standard.
The mechanical properties of ePTFE play a large role in determining its biomedical applications. These characteristics are often controlled during material fabrication. Examples are internodal distance and density, where specific requirements are met by adjusting the sintering, heating and stretching of the Teflon. 38 Therefore, various ePTFE vascular grafts and patches exhibit different porosities and densities. 39 Our HA-ePTFE process does not significantly alter the elastic modulus, tensile strength, yield stress, and ultimate strain of the ePTFE (Figure 6 ). The presented HA treatment technique is a seemingly feasible method to translate into commercial production, because no alteration of the base medical grade ePTFE is required. Future work will involve evaluating whether the treatment affects other mechanical properties such as pressurized burst strength, compliance, and relaxed and pressurized internal diameter. Although the mentioned parameters aim toward tubular grafts for bypasses, the HA enhancement technique can be used for other ePTFE-based biomaterials. In those cases, properties such as kink radius, suture retention strength, and diaphragm pressurized burst strength must be considered. Compliance mismatch is another issue facing synthetic ePTFE vascular grafts especially small diameter grafts, because the material characteristics of the ePTFE are significantly different from that of the soft small blood vessel it replaces. These differences cause increasing wall stress at the implant site. 40 How HA-ePTFE can overcome such challenges needs to be addressed in follow-up studies.
One noticeable result of enhancing ePTFE via spray coating is the shrinkage of the ePTFE graft by 25% longitudinally (nominal measurement). The HA-ePTFE tubular graft did recover approximately 15% when the biomaterial was hydrated, probably because the GAG swelled and rearranged. Nevertheless, the graft never fully recovered to its original length. Surprisingly, this shrinkage did not significantly change the elastic modulus, tensile strength, yield stress, or strain at failure. Future work will focus on preventing shrinkage, because this phenomenon could possibly affect other mechanical parameters.
Conclusions
A sustainable solution is needed to meet the increasing demand of cardiovascular implants. Success of these biomaterials relies on the improvement of promising synthetic materials such as ePTFE, which has been shown to cause protein adsorption and platelet activation that resulted in graft failure and surgical revision. This study attempted to address these problems by treating the lumen of the ePTFE graft with HA by spray coating. FTIR was used to characterize the surface of the material, which showed no fluorocarbon peaks of the original ePTFE, and the addition of the HA peaks. This finding, along with the HA coating evident in SEM images suggests complete HA coverage of the base material. The HA enhancement resulted in converting the surface of the ePTFE from hydrophobic to hydrophilic. The tendency of our biomaterial towards thrombosis was further tested through whole blood clotting and platelet activation. After exposure to whole blood, the HA-ePTFE resulted in less clotting than untreated ePTFE. A similar result occurred with platelet activation; HA-ePTFE showed a lower percentage of aggregated platelets when exposed to plasma. These two results, paired with no measurable cytotoxicity, lead to the conclusion that HA-ePTFE could effectively reduce thrombosis when used as a cardiovascular biomaterial. The HA enhancement can be applied directly to existing commercial ePTFE without significant changes in structural integrity, though further mechanical characterization is needed. Overall, HA-ePTFE, as described here, demonstrates strong potential to lower rates of device failure of cardiovascular medical implants.
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